Bioconversion of oleuropein

Patent metadata

Field	Value
Publication number	US-11504387-B2
Application number	US-201816762400-A
Country	US
Kind code	B2
Filing date	Nov 8, 2018
Priority date	Nov 8, 2017
Publication date	Nov 22, 2022
Grant date	Nov 22, 2022

Abstract

A composition contains at least one probiotic or enzyme selected from the group consisting of (i) a probiotic having β-glycosidase activity or a β-glycosidase, (ii) a probiotic having esterase activity or an esterase, (iii) a probiotic having both β-glycosidase activity and esterase activity or an enzyme having both β-glycosidase activity and esterase activity, (iv) a first probiotic having β-glycosidase activity and a second probiotic having esterase activity, (v) a probiotic having β-glycosidase activity and an esterase, (vi) a β-glycosidase and a probiotic having esterase activity and (vii) a β-glycosidase and an esterase. The at least one probiotic can form one or more of oleuropein aglycone, elenolic acid, hydroxytyrosol acetate or hydroxytyrosol from oleuropein. The composition can comprise oleuropein. The composition can be for treating or preventing impaired mobility in an older adult; stimulating bone formation and/or inhibiting bone resorption; treating or preventing synovitis in an individual in need or at risk thereof or treating or preventing articular cartilage degradation subsequent to synovitis in an individual having or recovering from synovitis; or preventing or treating cartilage breakdown.

First claim

The invention is claimed as follows:

1. A method of treating impaired mobility in an older adult being a low absorber or a non absorber of oleuropein, the method comprising orally administering to the older adult an effective amount of a composition comprising oleuropein and at least one probiotic selected from the group consisting of Bifidobacterium longum ATCC BAA-999, Bifidobacterium longum CNCM 1-2618, Bifidobacterium animalis CNCM 1-3446, Streptococcus thermophilus CNCM 1-3915, Lactobacillus paracasei CNCM 1-2116, Lactobacillus rhamnosus CGMCC 1.3724, Lactobacillus johnsonii CNCM 1-1225 and Lactococcus lactis CNCM 1-4154, and the composition does not contain rutin, wherein said low absorber or non absorber of oleuropein is a result of the older adult having an intestinal microbiota lacking or low in bacteria having β-glycosidase activity and/or lacking or low in bacteria having esterase activity.

2. The method of claim 1 , wherein the older adult is an elderly individual.

3. The method of claim 1 , wherein the older adult has a condition selected from the group consisting of frailty, pre-frailty, sarcopenia, recovering from sarcopenia, osteoporosis, osteoarthritis, malnutrition, at risk of malnutrition, undergoing rehabilitation, scheduled to undergo rehabilitation within the next year, and combinations thereof.

4. A method for stimulating bone formation and/or inhibiting bone resorption in an individual having a condition comprising an imbalance between bone formation and bone resorption, the method comprising orally administering to the individual an effective amount of a composition comprising oleuropein and at least one probiotic selected from the group consisting of Bifidobacterium longum ATCC BAA-999 , Bifidobacterium longum CNCM 1-2618 , Bifidobacterium animalis CNCM 1-3446 , Streptococcus thermophilus CNCM 1-3915 , Lactobacillus paracasei CNCM 1-2116 , Lactobacillus rhamnosus CGMCC 1.3724 , Lactobacillus johnsonii CNCM 1-1225 and Lactococcus lactis CNCM 1-4154, and the composition does not contain rutin, and the individual is a low absorber or a non absorber of oleuropein, wherein said low absorber or non absorber of oleuropein is a result of the individual having an intestinal microbiota lacking or low in bacteria having β-glycosidase activity and/or lacking or low in bacteria having esterase activity.

5. The method of claim 4 , wherein the condition is selected from the group consisting of osteoporosis, Paget's disease, osteolysis adjacent a prosthesis, a metastatic bone disease, hyperthyroidism, hypercalcemia due to a cancer, multiple myelomas, a periodontal disease, osteoarthritis, osteopenia, a bone deficit resulting from a fracture, fracture healing, and combinations thereof.

6. A method of treating synovitis in an individual in need thereof, treating articular cartilage degradation subsequent to synovitis in an individual having r recovering from synovitis, the method comprising orally administering to the individual an effective amount of a composition comprising oleuropein and at least one probiotic selected from the group consisting of Bifidobacterium longum ATCC BAA-999 , Bifidobacterium longum CNCM 1-2618 , Bifidobacterium animalis CNCM 1-3446 , Streptococcus thermophilus CNCM 1-3915 , Lactobacillus paracasei CNCM 1-2116 , Lactobacillus rhamnosus CGMCC 1.3724 , Lactobacillus johnsonii CNCM 1-1225 and Lactococcus lactis CNCM 1-4154, and the composition does not contain rutin, and the individual is a low absorber or a non absorber of oleuropein, wherein said low absorber or non absorber of oleuropein is a result of the individual having an intestinal microbiota lacking or low in bacteria having β-glycosidase activity and/or lacking or low in bacteria having esterase activity.

7. The method of claim 6 wherein the synovitis is associated with a condition selected from the group consisting of lupus, gout, rheumatoid arthritis, osteoarthritis, osteochondritis disease, osteoarthrosis and combinations thereof.

8. The method of claim 1 , wherein the composition is administered in the effective amount to enhance absorption of the oleuropein.

9. The method of claim 4 , wherein the composition is administered in the effective amount to enhance absorption of the oleuropein.

10. The method of claim 6 , wherein the composition is administered in the effective amount to enhance absorption of the oleuropein.

Assignees

• Nestle Sa

Inventors

• Horcajada Marie Noelle
• Duboux Stephane
• Poquet Laure

Classifications

• A61K36/63

  Oleaceae (Olive family), e.g. jasmine, lilac or ash tree · CPC title

• A61K31/7048 Primary

  having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin} · CPC title

• A61K35/741

  Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06) · CPC title

• A61K38/465

  acting on ester bonds (3.1), e.g. lipases, ribonucleases · CPC title

• C12Y302/01097

  Glycopeptide alpha-N-acetylgalactosaminidase (3.2.1.97) · CPC title